Evidence map›Paper›PMID 42155637›Full record

ArticleMolecular metabolism2026

Metabolic plasticity and optimal redox homeostasis are essential for efficient metastatic colonization.

Ece Grace, Deyu Zou, Romy Böttcher-Loschinski, Martin Böttcher, Harald Schuhwerk, Yussuf Hajjaj, Annemarie Schwab, Simon Brandt, Ana Clavel Ezquerra, Witold Szymanski and 14 more

Erratum issuedAbstract read
In one paragraph

Article in Molecular metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Ece GraceDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Deyu ZouDepartment of Hematology, Oncology and Cell Therapy, Otto-von-Guericke-University of Magdeburg, Magdeburg, Germany.
Romy Böttcher-LoschinskiDepartment of Hematology, Oncology and Cell Therapy, Otto-von-Guericke-University of Magdeburg, Magdeburg, Germany; Magdeburg Centre for Cell and Immune Therapy (MAZI), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Martin BöttcherDepartment of Hematology, Oncology and Cell Therapy, Otto-von-Guericke-University of Magdeburg, Magdeburg, Germany; Magdeburg Centre for Cell and Immune Therapy (MAZI), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Healthcampus Immunology, Inflammation and Infectiology (GC-I3), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Harald SchuhwerkDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany; Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
Yussuf HajjajDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Annemarie SchwabDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Simon BrandtDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Ana Clavel EzquerraDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Witold SzymanskiInstitute of Translational Proteomics & Core Facility Translational Proteomics, Philipps-Universität Marburg, Marburg, Germany.
Johannes GraumannInstitute of Translational Proteomics & Core Facility Translational Proteomics, Philipps-Universität Marburg, Marburg, Germany.
Philipp ArnoldInstitute of Functional and Clinical Anatomy, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Renato LiguoriDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany; Department of Nephropathology, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Fulvia FerrazziDepartment of Nephropathology, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Constantin P KrempeDepartment of Dermatology, University Hospital Essen, German Cancer Consortium (DKTK) and Research Alliance Ruhr, Research Center One Health, Campus Essen, Essen, Germany; Applied Analytical Chemistry, University of Duisburg-Essen, Essen, Germany.
L M Nascentes MeloDepartment of Dermatology, University Hospital Essen, German Cancer Consortium (DKTK) and Research Alliance Ruhr, Research Center One Health, Campus Essen, Essen, Germany.
Gabriele AlliesDepartment of Dermatology, University Hospital Essen, German Cancer Consortium (DKTK) and Research Alliance Ruhr, Research Center One Health, Campus Essen, Essen, Germany.
Sven W MeckelmannApplied Analytical Chemistry, University of Duisburg-Essen, Essen, Germany.
Dirk MielenzDepartment of Translational Immunology, Department of Internal Medicine 3, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Simone BrabletzDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Dimitrios MougiakakosDepartment of Hematology, Oncology and Cell Therapy, Otto-von-Guericke-University of Magdeburg, Magdeburg, Germany; Magdeburg Centre for Cell and Immune Therapy (MAZI), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Healthcampus Immunology, Inflammation and Infectiology (GC-I3), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Health and Medical Prevention - CHAMP, Otto-von-Guericke University, Magdeburg, Germany.
Alpaslan TasdoganDepartment of Dermatology, University Hospital Essen, German Cancer Consortium (DKTK) and Research Alliance Ruhr, Research Center One Health, Campus Essen, Essen, Germany.
Thomas BrabletzDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Marc P StemmlerDepartment of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular Medicine, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Erlangen, Germany. Electronic address: marc.stemmler@fau.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cells dynamically reprogram their metabolism to adapt to changing microenvironmental conditions during tumor growth and metastatic dissemination. Metastasis of solid tumors-the principal cause of cancer-related mortality-is often driven through activation of epithelial-mesenchymal transition (EMT), regulated by the transcription factor ZEB1, which is frequently upregulated during tumor progression. To investigate the role of metabolic plasticity in metastasis, we employed murine pancreatic ductal adenocarcinoma (PDAC) cell lines with distinct EMT states, ZEB1 expression and lung colonization capacities. Highly plastic epithelial-type cancer cells (KPCepi) efficiently colonize the lung, whereas Zeb1-deficient cancer cells (KPCZ) with compromised metabolic plasticity show markedly reduced colonization, correlated with absent glycolytic reserve, mitochondrial dysfunction, and reduced anti-oxidant metabolite levels. Interestingly, mesenchymal-type cancer cells (KPCmes) also exhibit poor lung colonization despite retaining normal glycolytic capacity and a high proportion of functional mitochondria; however, similar to KPCZ cells, they display diminished levels of detoxifying metabolites. Low metastatic capacity correlates with increased susceptibility to ferroptosis even in epithelial-type KPCZ cells, indicating a limited ability to counteract reactive oxygen species under stress. Together, these findings demonstrate that metabolic plasticity and redox homeostasis are essential prerequisites for efficient lung colonization. Thus, concurrent targeting of metabolic adaptability and redox buffering may represent a promising strategy to prevent metastasis in aggressive PDAC tumors.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsCell Line, TumorEpithelial-Mesenchymal TransitionFerroptosisGlycolysisHomeostasisHumansLung NeoplasmsMetabolic ReprogrammingMiceMitochondriaNeoplasm MetastasisOxidation-ReductionReactive Oxygen SpeciesReactive Oxygen SpeciesZinc Finger E-box-Binding Homeobox 1CancerCellular plasticityEpithelial-to-mesenchymal transitionFerroptosisGlycolysisMetabolismMetastasisMitochondriaPancreatic ductal adenocarcinoma (PDAC)Redox balance

Identifiers

PMID42155637
PMCPMC13240752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.